Tuberculosis: A Persistent Global health Crisis Despite Progress
Table of Contents
Tuberculosis (TB) remains a leading cause of death worldwide, disproportionately impacting vulnerable populations in specific regions. According to a recent World health organization (WHO) report, teh countries bearing the heaviest burden of TB are India, Indonesia, the Philippines, Nigeria, Pakistan, the Democratic Republic of congo, adn Bangladesh.
this concentration isn’t accidental. The report highlights a strong correlation between TB prevalence and five key risk factors: malnutrition, HIV infection, diabetes, tobacco use, and alcohol-related disorders.These social and behavioral determinants transform a perhaps preventable disease into a chronic health crisis for those already facing hardship.
The situation is particularly dire for individuals living with HIV, where TB is the leading cause of mortality, accounting for 150,000 deaths last year. This illustrates a perilous cycle where multiple health issues exacerbate one another.
[Image of 100x magnified microscopic image of AFB staining. Microbacterium tuberculosis (MTB) – Credit: Md. Ariful Islam]
Fragile Gains Threatened by Funding Shortfalls
Despite disruptions caused by the COVID-19 pandemic, recent indicators show a glimmer of hope. TB-related deaths decreased by three percent compared to 2023, and the number of reported cases fell by almost two percent. In 2024, a record 8.3 million people were diagnosed and began treatment, with treatment success rates rising from 68 to 71 percent.
These advancements have collectively saved an estimated 83 million lives as 2000, demonstrating the effectiveness of large-scale interventions. though, Tereza Kasaeva, head of the relevant department at the WHO, warns that these gains are at risk due to budget cuts and ongoing epidemiological challenges.
A critical issue is insufficient funding. In 2024, only $5.9 billion was allocated to TB prevention, diagnosis, and treatment - significantly less than the $22 billion annual target set for 2027. This chronic underfunding, wich has remained stagnant since 2020, contributes to the continued high mortality rate of a curable disease.
Innovation Offers a path Forward
Scientific research is providing encouraging developments.Currently, 63 new diagnostic tests are in advancement, 29 new drugs are undergoing clinical trials, and 18 vaccine candidates are being tested on humans, with six in the crucial phase three stage.
Artificial intelligence is also being deployed, offering tools for faster and more accurate TB detection than conventional methods. These technological advancements, coupled with shorter and more effective treatment regimens, are gradually improving the fight against TB, particularly in resource-constrained settings.
Despite its devastating impact, a new TB vaccine hasn’t been approved in over a century. The current vaccine, BCG, is only used in childhood vaccination programs, and no vaccine exists for adults. This lack of vaccine options for such a deadly disease raises questions about the priorities within global pharmaceutical research.
